Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …

Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …